Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers. (July 2017)

• Record Type: Journal Article
• Authors: Simon, Thomas; Pogu, Julien; Rémy, Séverine; Brau, Frédéric; Pogu, Sylvie; Maquigneau, Maud; Fonteneau, Jean-François; Poirier, Nicolas; Vanhove, Bernard; Blancho, Gilles; Piaggio, Eliane; Anegon, Ignacio; Blancou, Philippe
• Is Part Of: Journal of autoimmunity. Volume 81(2017)
• Page Start: 44
• Page End: 55
• Publication Date: 2017-07
• Subjects: Autoimmunity -- Heme oxygenase-1 -- T-lymphocyte -- Migration -- Diabetes -- Auto-immune encephalomyelitis -- Delayed type hypersensitivity -- Tolerance -- Monocyte-derived dendritic cells; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; Autoantibodies -- Periodicals; Autoimmune Diseases -- Periodicals; Auto-immunité -- Périodiques; Maladies auto-immunes -- Périodiques; Electronic journals; 616.978005
• DOI: 10.1016/j.jaut.2017.03.005
• Languages: English
• ISSNs: 0896-8411

Abstract

Abstract: Developing protocols aimed at inhibiting effector T cells would be key for the treatment of T cell-dependent autoimmune diseases including type 1 autoimmune diabetes (T1D) and multiple sclerosis (MS). While heme oxygenase-1 (HO-1) inducers are clinically approved drugs for non-immune-related diseases, they do have immunosuppressive properties when administered systemically in rodents. Here we show that HO-1 inducers inhibit antigen-specific effector T cells when injected intradermally together with the T cell cognate antigens in mice. This phenomenon was observed in both a CD8 + T cell-mediated model of T1D and in a CD4 + T cell-dependent MS model. Intradermal injection of HO-1 inducers induced the recruitment of HO-1 + monocyte-derived dendritic cell (MoDCs) exclusively to the lymph nodes (LN) draining the site of intradermal injection. After encountering HO-1 + MoDCs, effector T-cells exhibited a lower velocity and a reduced ability to migrate towards chemokine gradients resulting in impaired accumulation to the inflamed organ. Intradermal co-injection of a clinically approved HO-1 inducer and a specific antigen to non-human primates also induced HO-1 + MoDCs to accumulate in dermal draining LN and to suppress delayed-type hypersensitivity. Therefore, in both mice and non-human primates, HO-1 inducers delivered locally inhibited effector T-cells in an antigen-specific manner, paving the way for repositioning these drugs for the treatment of immune-mediated diseases. Highlights: I.d. injection of HO-1 inducer and antigen inhibits antigen-specific effector T cells. MoDC can inhibit effector T-cells showing a broader role than previously appreciated. Clinically approved HO-1 inducer inhibits antigen-specific T cells in primates.